{"pmid":32209598,"title":"COVID-19 Challenges Basic Researchers.","text":["COVID-19 Challenges Basic Researchers.","As COVID-19 continues to surge, cancer scientists engaged in basic research face unique challenges. At centers throughout the United States, investigators are confronting difficult decisions about which experiments to continue, while securing supplies and creating contingency plans for a complete shutdown.","Cancer Discov","32209598"],"abstract":["As COVID-19 continues to surge, cancer scientists engaged in basic research face unique challenges. At centers throughout the United States, investigators are confronting difficult decisions about which experiments to continue, while securing supplies and creating contingency plans for a complete shutdown."],"journal":"Cancer Discov","date":"2020-03-27T11:00:00Z","year":2020,"_id":"32209598","week":"202013|Mar 23 - Mar 29","doi":"10.1158/2159-8290.CD-NB2020-018","source":"PubMed","locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["General Info"],"weight":1,"_version_":1662444220189769728,"score":7.208847,"similar":[{"pmid":32197238,"title":"Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal.","text":["Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal.","The first confirmed case of coronavirus disease 2019 (COVID-19) in the United States was reported on January 20, 2020, in Snohomish County, Washington. At the epicenter of COVID-19 in the United States, the Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, and University of Washington are at the forefront of delivering care to patients with cancer during this public health crisis. This Special Feature highlights the unique circumstances and challenges of cancer treatment amidst this global pandemic, and the importance of organizational structure, preparation, agility, and a shared vision for continuing to provide cancer treatment to patients in the face of uncertainty and rapid change.","J Natl Compr Canc Netw","Ueda, Masumi","Martins, Renato","Hendrie, Paul C","McDonnell, Terry","Crews, Jennie R","Wong, Tracy L","McCreery, Brittany","Jagels, Barbara","Crane, Aaron","Byrd, David R","Pergam, Steven A","Davidson, Nancy E","Liu, Catherine","Stewart, F Marc","32197238"],"abstract":["The first confirmed case of coronavirus disease 2019 (COVID-19) in the United States was reported on January 20, 2020, in Snohomish County, Washington. At the epicenter of COVID-19 in the United States, the Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, and University of Washington are at the forefront of delivering care to patients with cancer during this public health crisis. This Special Feature highlights the unique circumstances and challenges of cancer treatment amidst this global pandemic, and the importance of organizational structure, preparation, agility, and a shared vision for continuing to provide cancer treatment to patients in the face of uncertainty and rapid change."],"journal":"J Natl Compr Canc Netw","authors":["Ueda, Masumi","Martins, Renato","Hendrie, Paul C","McDonnell, Terry","Crews, Jennie R","Wong, Tracy L","McCreery, Brittany","Jagels, Barbara","Crane, Aaron","Byrd, David R","Pergam, Steven A","Davidson, Nancy E","Liu, Catherine","Stewart, F Marc"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32197238","week":"202012|Mar 16 - Mar 22","doi":"10.6004/jnccn.2020.7560","source":"PubMed","locations":["Snohomish County","United States","Washington"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Treatment"],"weight":1,"_version_":1662334543188721664,"score":125.86008},{"pmid":32191623,"title":"The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks.","text":["The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks.","Coronavirus disease 2019, abbreviated to COVID-19 and sustained by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the latest biological hazard to assume the relevance of insidious worldwide threat. One obvious question that is now engaging the minds of many scientists and healthcare professionals is whether and eventually how laboratory medicine could efficiently contribute to counteract this and other (future) viral outbreaks. Despite there being evidence that laboratory tests are vital throughout many clinical pathways, there are at least three major areas where in vitro diagnostics can also provide essential contributions to diagnostic reasoning and managed care of patients with suspected or confirmed SARS-CoV-2 infection. These include etiological diagnosis, patient monitoring, as well as epidemiologic surveillance. Nonetheless, some structural and practical aspects may generate substantial hurdles in providing timely and efficient response to this infectious emergency, which basically include inadequate (insufficient) environment and shortage of technical and human resources for facing enhanced volume of tests on many infected patients, some of whom are with severe disease. Some proactive and reactive strategies may hence be identified to confront this serious healthcare challenge, which entail major investments on conventional laboratory resources, reinforcement of regional networks of clinical laboratories, installation of mobile laboratories, as well as being proactive in establishing laboratory emergency plans.","Clin Chem Lab Med","Lippi, Giuseppe","Plebani, Mario","32191623"],"abstract":["Coronavirus disease 2019, abbreviated to COVID-19 and sustained by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the latest biological hazard to assume the relevance of insidious worldwide threat. One obvious question that is now engaging the minds of many scientists and healthcare professionals is whether and eventually how laboratory medicine could efficiently contribute to counteract this and other (future) viral outbreaks. Despite there being evidence that laboratory tests are vital throughout many clinical pathways, there are at least three major areas where in vitro diagnostics can also provide essential contributions to diagnostic reasoning and managed care of patients with suspected or confirmed SARS-CoV-2 infection. These include etiological diagnosis, patient monitoring, as well as epidemiologic surveillance. Nonetheless, some structural and practical aspects may generate substantial hurdles in providing timely and efficient response to this infectious emergency, which basically include inadequate (insufficient) environment and shortage of technical and human resources for facing enhanced volume of tests on many infected patients, some of whom are with severe disease. Some proactive and reactive strategies may hence be identified to confront this serious healthcare challenge, which entail major investments on conventional laboratory resources, reinforcement of regional networks of clinical laboratories, installation of mobile laboratories, as well as being proactive in establishing laboratory emergency plans."],"journal":"Clin Chem Lab Med","authors":["Lippi, Giuseppe","Plebani, Mario"],"date":"2020-03-20T11:00:00Z","year":2020,"_id":"32191623","week":"202012|Mar 16 - Mar 22","doi":"10.1515/cclm-2020-0240","keywords":["COVID-19","coronavirus","laboratory medicine","laboratory tests"],"source":"PubMed","topics":["Diagnosis","Prevention"],"weight":1,"_version_":1662334543451914240,"score":92.887375},{"pmid":32053389,"title":"Straining the System: Novel Coronavirus (COVID-19) and Preparedness for Concomitant Disasters.","text":["Straining the System: Novel Coronavirus (COVID-19) and Preparedness for Concomitant Disasters.","Just a few weeks before the first confirmed case of novel coronavirus (COVID-19) was reported in the United States, the US Centers for Disease Control and Prevention (CDC) issued a bold promise to the nation: the agency will use its scientific expertise to bring a new level of preparedness in the United States and global health security against current and growing threats, finally eliminate certain diseases, and bring an end to the devastation of epidemics.(1) The current outbreak of COVID-19 reminds us how urgent this promise is and just how critical it is to continue to sustain and strengthen our nation's public health infrastructure. The unprecedented pace of the public health response to COVID-19 has only been possible because of prior investments in public health preparedness. To accelerate our pace and meet the challenges of current and future health threats, we must advance our world-class data and analytics capabilities; maintain and expand our state-of-the-art public health laboratory capacity; continue building a workforce of trusted, expert, public health professionals; sustain our capacity to rapidly respond to outbreaks at their source; and assure a strong global and domestic preparedness capacity. (Am J Public Health. Published online ahead of print February 13, 2020: e1-e2. doi:10.2105/AJPH.2020.305618).","Am J Public Health","Smith, Nathaniel","Fraser, Michael","32053389"],"abstract":["Just a few weeks before the first confirmed case of novel coronavirus (COVID-19) was reported in the United States, the US Centers for Disease Control and Prevention (CDC) issued a bold promise to the nation: the agency will use its scientific expertise to bring a new level of preparedness in the United States and global health security against current and growing threats, finally eliminate certain diseases, and bring an end to the devastation of epidemics.(1) The current outbreak of COVID-19 reminds us how urgent this promise is and just how critical it is to continue to sustain and strengthen our nation's public health infrastructure. The unprecedented pace of the public health response to COVID-19 has only been possible because of prior investments in public health preparedness. To accelerate our pace and meet the challenges of current and future health threats, we must advance our world-class data and analytics capabilities; maintain and expand our state-of-the-art public health laboratory capacity; continue building a workforce of trusted, expert, public health professionals; sustain our capacity to rapidly respond to outbreaks at their source; and assure a strong global and domestic preparedness capacity. (Am J Public Health. Published online ahead of print February 13, 2020: e1-e2. doi:10.2105/AJPH.2020.305618)."],"journal":"Am J Public Health","authors":["Smith, Nathaniel","Fraser, Michael"],"date":"2020-02-14T11:00:00Z","year":2020,"_id":"32053389","week":"20207|Feb 10 - Feb 16","doi":"10.2105/AJPH.2020.305618","source":"PubMed","locations":["United States"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1662334544500490241,"score":81.271614},{"pmid":32216865,"title":"Translating COVID-19 Pandemic Surge Theory to Practice in the Emergency Department: How to Expand Structure.","text":["Translating COVID-19 Pandemic Surge Theory to Practice in the Emergency Department: How to Expand Structure.","Multiple professional societies, nongovernment and government agencies have studied the science of sudden onset disaster mass casualty incidents to create and promote surge response guidelines. The COVID-19 pandemic has presented the health care system with challenges that have limited science to guide the staff, stuff and structure surge response.This study reviewed the available surge science literature specifically to guide an Emergency Department's surge structural response using a translational science approach to answer the question: How does the concept of sudden onset mass casualty incident (MCI) surge capability apply to the process to expand COVID-19 Pandemic surge structure response?The available surge structural science literature was reviewed to determine the application to a pandemic response. The on-line ahead of print and print COVID-19 scientific publications, as well as grey, literature were studied to learn the best available COVID-19 surge structural response science. A checklist was created to guide the Emergency Department team's COVID-19 surge structural response.","Disaster Med Public Health Prep","Paganini, Matteo","Conti, Andrea","Weinstein, Eric","Della Corte, Francesco","Ragazzoni, Luca","32216865"],"abstract":["Multiple professional societies, nongovernment and government agencies have studied the science of sudden onset disaster mass casualty incidents to create and promote surge response guidelines. The COVID-19 pandemic has presented the health care system with challenges that have limited science to guide the staff, stuff and structure surge response.This study reviewed the available surge science literature specifically to guide an Emergency Department's surge structural response using a translational science approach to answer the question: How does the concept of sudden onset mass casualty incident (MCI) surge capability apply to the process to expand COVID-19 Pandemic surge structure response?The available surge structural science literature was reviewed to determine the application to a pandemic response. The on-line ahead of print and print COVID-19 scientific publications, as well as grey, literature were studied to learn the best available COVID-19 surge structural response science. A checklist was created to guide the Emergency Department team's COVID-19 surge structural response."],"journal":"Disaster Med Public Health Prep","authors":["Paganini, Matteo","Conti, Andrea","Weinstein, Eric","Della Corte, Francesco","Ragazzoni, Luca"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32216865","week":"202013|Mar 23 - Mar 29","doi":"10.1017/dmp.2020.57","keywords":["COVID-19","Pandemics","SARS-CoV-2","Surge Capacity","Translational Science"],"source":"PubMed","weight":0,"_version_":1662540582131597312,"score":77.92633},{"pmid":32192297,"title":"[Chemotherapy strategy for colorectal cancer under the outbreak of corona virus disease 2019].","text":["[Chemotherapy strategy for colorectal cancer under the outbreak of corona virus disease 2019].","The outbreak of corona virus disease 2019 (COVID-19) makes the medical treatment of colorectal cancers difficult. Cancer patients are more susceptible to infection and tumor history is defined as an important factor of poor prognosis, which challenges both doctors and patients. For metastatic colorectal cancer (CRC) patients, maintenance therapy is the optimal choice. The patients with tumor progression or poor biological behavior should receive or continue combination chemotherapy. Adjuvant chemotherapy should reduce the intensity of treatment and shorten the therapy time. Fever patients during chemotherapy need to receive differential diagnosis and screening according to national standards. Patients with stable diseases and good general conditions may delay imaging examination. Clinicians should make individual clinical decisions based on the specifics of each patient during epidemic situation.","Zhonghua Wei Chang Wai Ke Za Zhi","Li, Y H","Shen, L","Li, J","32192297"],"abstract":["The outbreak of corona virus disease 2019 (COVID-19) makes the medical treatment of colorectal cancers difficult. Cancer patients are more susceptible to infection and tumor history is defined as an important factor of poor prognosis, which challenges both doctors and patients. For metastatic colorectal cancer (CRC) patients, maintenance therapy is the optimal choice. The patients with tumor progression or poor biological behavior should receive or continue combination chemotherapy. Adjuvant chemotherapy should reduce the intensity of treatment and shorten the therapy time. Fever patients during chemotherapy need to receive differential diagnosis and screening according to national standards. Patients with stable diseases and good general conditions may delay imaging examination. Clinicians should make individual clinical decisions based on the specifics of each patient during epidemic situation."],"journal":"Zhonghua Wei Chang Wai Ke Za Zhi","authors":["Li, Y H","Shen, L","Li, J"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32192297","week":"202012|Mar 16 - Mar 22","doi":"10.3760/cma.j.cn.441530-20200225-00089","keywords":["Chemotherapy","Colorectal neoplasms","Corona virus disease 2019"],"source":"PubMed","locations":["Clinicians"],"topics":["Treatment"],"weight":1,"_version_":1662334543193964544,"score":77.71401}]}